Acquisition Exempted Shares Actions Connection Distribution
Additional Capital Not Available Curtail Cease Operations Additional Details Regarding Historical Results Period-over-period Variances Summarized
Additional Provisions Additional Representations Trubion
Adjustments After Conclusion Prepared Remarks Open Call Questions Ensure
Allocation Also Constitute Surrender Transfer Rights Associated Common Stock
Amendment Amendment Rights Agreement
Amendment Triple Net Space Lease Amendments Agreement Not Modified Amended Except Writing Signed
Amendments Articles Incorporation Bylaws Change Ancillary Agreements Shall Been Entered Parties Other Thereto
Andrew Guggenhime Andrew Guggenhime Facet Biotech Corp Svp Cfo
Annual Incentive Grants Anticipate Incur Losses Foreseeable Future Never Achieve Sustain
Arbitration Asset Impairment Charges
Assignment Attendance Annual Meetings Directors
Attract Retain Highly Skilled Employees Order Succeed Audits
Aug Available Information
Base Salary Basis Presentation
Bear Cost Soliciting Proxies Annual Meeting Before Distribution Date Pdl Shall Transfer Facet Employees
Biogen Idec Incs Tender Offer Facet Biotechs Common Board Committee Meetings 2008
Board Directors Pdl Shall Authorized Approved Distribution Not Board Directors Recommend Vote
Board Directors Shall Mean Books Records
Breach Bristol-myers Squibb
Bristol-myers Squibb Forward-looking Statements Business Strategy Dependent Ability In-license Otherwise Acquire Rights
Calculation Adjustment Payment Selected Liabilities Candidates Nomination Director
Capitalized Software Cash Compensation
Cash Equivalents Concentration Credit Risk Cash Incentive Bonuses
Cash Retention Bonus Program Cash Utilization 2009
Certain Covenants Other Agreements Parties Certification
Certifications Change Control Severance Benefits
Changes Internal Control Over Financial Reporting Changes International Health Care Industry Including Regarding Reimbursement
Clinical Development Drug Products Inherently Uncertain Expensive Subject Clinical Trial Expenses
Collaboration Agreements Collaboration License Agreement
Collaboration Products Collaborations Not Successful Terminated Collaborators Effectively Develop Market
Collaborative Arrangements Collaborative Licensing Agreements
Commercialization Costs Accounts Commercialization Plan
Commitments Company-wide Restructuring
Comparison Stockholder Returns Compensation Committee Interlocks Insider Participation
Competition Compliance Laws Governmental Requirements
Comply Extensive Government Regulations Laws Composition
Comprehensive Loss Conference Call Participants
Conference Call Webcast Confidential Information
Confidentiality Consequences Opt-out
Consolidated Balance Sheet Data Consolidated Party
Consolidation Construction
Consultation Reporting Review Contact Board Directors Committee
Contingencies Continuation
Continuing Rights Obligations Contractors
Controls Procedures Cooperation Exchange Information
Costs Associated Exit Disposal Activities Counterparts
Critical Accounting Policies Estimates Cumulative Royalties
Currency Current Report Pursuant Securities Exchange Act 1934
Daclizumab Decision-making
Decisions Deferred Transfers Assumptions
Definitions Departure Directors Certain Officers Election Appointment Compensatory
Determination Amounts Development Cost Accounts
Development Responsibilities Did Receive Proxy Statement
Disclaimer Disclaimer Limitation Liability
Disclosure Inventions Discontinuation Participation Committee
Dispute Resolution Dispute Resolution Arbitration Except Provided Non-exclusive Cross-license Agreement
Disputed Breach Distribution
Divisional Patent Application Documents Incorporated Reference
Earnings Per Share Economic Industry-wide Factors
Effect Termination Trubion Uncured Breach Effective 2008
Effects Termination Facet Elotuzumab
Employee Benefits Employee Matters Agreement
Employees End Reviewed Significant Number Opportunities Over Past Several
Enforcement Patent Rights After Opt-out Enforcement Patent Rights Before Opt-out
Engineering Work Performed Commercial Antibodies Presented Enters Agreement Biotechnology Value Fund Facet Biotechs Largest
Entire Agreement Parties Entitled Vote Annual Meeting
Entry Material Definitive Agreement Environmental Compliance
Equity Compensation Equity Compensation Plan Information
Equity Incentives Equity Investment
Evaluation Director Nominations Evaluation Disclosure Controls Procedures
Exact Name Registrant Specified Charter Example Not Expect Receive Milestone Payment Biogen Idec
Exchange Act Shall Mean Securities 1934 Amended Exclusivity
Exhibits Expense Insurer Provided However Nothing Shall Deemed Constitute
Expiration Royalty Period Extraordinary Notices
Face Significant Competition Facet Biotech
Facet Biotech Confirms Receipt Biogen Idec Letter Facet Biotech Corporation
Facet Biotech Elects Hoyoung Huh Phd Board Directors Facet Biotech Elects Kurt Von Emster Board Directors
Facet Biotech Forward Looking Statements Facet Biotech Forward-looking Statements
Facet Biotech Receives Director Nomination Notice Facet Biotech Reports 2009 Financial Results
Facet Biotech Responds Roderick Wong Letter Press Release Facet Collaboration Patent Rights
Facet Forward-looking Statements Facet Royalties
Facilities-related Restructuring Facility Audits
Factors Cause Differences Between Current Expectations Actual Results Faheem Hasnain
Faheem Hasnain Facet Biotech Corp President Ceo Failure Executive Officers Resolve Dispute
Failure Gain Market Acceptance Product Candidates Among Medical Fair Value Measurements
Federal Excise Tax 4999 Code Financial Statements Exhibits
Force Majeure Foreign Currency Translation
Form 10-k Form Shall Been Declared Effective Sec Stop Order
Formation Composition Formation Purpose
Forward-looking Statements France Restructuring Plan
French Office Restructuring Fte Records Calculations
Further Actions Further Assurances
Further Provided Gain Sale Assets
General General Administrative Expenses
Governing Law Government Approvals
Government Regulation Governmental Approvals Consents
Great Thanks Faheem Good Afternoon Everyone Ill Start Guidance
Historical Financial Information Not Necessarily Indicative Future Position History Operating Independent Evaluate
Humanization Agreements Immediate Release
Impairment Long Lived Assets Implied Rights
Important Information Important Information Solicitation Participants Legend
In-licensing Agreements Income Taxes
Incur Significant Costs Order Comply Environmental Regulations Defend Ind
Indemnification After Opt-out Indemnification Taxes
Indemnity Independent Contractors
Independent Directors Index
Information Settlement Initial Development Plan
Insurance Intangible Assets
Intangible Other Long-lived Assets Intellectual Property
Intentionally Omitted Interest Other Income Expense
Interest Past Due Payments Internal Controls Procedures
Jason Jason Zhang
Jean Suzuki Jean Suzuki Facet Biotech Corp
Joint Sublicense Land Property Equipment
Leases Legal Proceedings
Let Begin Exciting News Lead Pipeline Candidate Daclizumab Let Take Through Objectives Discuss Progress Each Half
License Facet Licenses
Licenses Trubion Limitation Liability
Limitations Authority Committees Limitations Development
Limitations Effectiveness Controls Limitations Indemnification
List Exhibits List Schedules
Litigation Directly Indirectly Resulting Biogen Idecs Unsolicited Tender Long-term Liabilities
Looking Ahead Longer-term Todays Announcement Not Impact View Major Customers
Management Estimates Maninder Hora
Manufacturing Changes Result Delays Obtaining Regulatory Approval Marketing Manufacturing Restructuring
Market Price Shares Fluctuate Widely Marks
Material Compensatory Plans Contracts Arrangements Material Government Approvals Other Consents Necessary Consummate Separation
Mccamish Medical Education Activities
Meetings Meetings Jfc
Meetings Jpc Membership Jfc
Membership Jpc Mike King
Mike Let Step Back 3319 Cash Related Balance Milestones
Minimum Purchase Commitments Miscellaneous
Moderator Introduction Most Recent Cash Utilization Was 123 Bringing Half
Multiple Sclerosis Mutual Covenant
Mutual Indemnification Nasdaq Shall Meaning Set Forth Hereof
Nda Need Obtain Patent Licenses Others Order Manufacture Sell
Net Loss Was 408 171 Per Basic Diluted New Hire Grants
Non-exclusive Cross License Agreement Non-monetary Transaction
Non-solicitation Not Only Validate Technology Hopefully Value
Not Receive Contingent Consideration Related Sale Product Rights Notice Annual Meeting Stockholders
Notice Consultation Notice Contest Claim
Notification Litigation Now Consistent Ongoing Select Study Biogen Idec Conduct
Now Like Step Back Provide Bigger Picture View Now Next Present Ectrims Meeting Dusseldorf Provide Insight
Now Program Represents Significant Potential Financial Upside Facet Now Therefore
Number 001-34154 Obligations Respect Party Contracts
Obtain Future Financing Through Issuance Debt Equity Adverse Off Always Said Appropriate Offer Was Put Table
Okay Then Ask Another Question Operating Expenses Results Future Revenue Likely Fluctuate Periods
Operator Operator Instructions Further Questions Like Turn Call Over
Opt-out Opt-out Effective Date
Opt-out Option Opt-out Option Following Change Control
Ordinary Notices Organization Business
Other Other Accrued Liabilities
Other Events Other Expenses
Other Income Expense Net Interest Other Information
Other Party Claims Other Remedies
Out-license Agreements Out-licensing Agreements
Overview Ownership Collaboration Inventions
Participants Participants Facet Biotech Corporation
Party Liable Settlement Effected Without Consent Not Unreasonably Party Licenses
Patent Trademark Disputes Patents Licensed Parties
Patents Other Intellectual Proprietary Rights Payment
Payment Rights Holder Applicable Taxes Charges Unless Until Payments
Pdl Shall Give Exchange Not Less Advance Notice Pdls Employee Stock Purchase Plan
Pdls Stock-based Incentive Plans Peer Group Selection Benchmarking
Percentage Ownership Facet Biotech Diluted Future Performance Bonus Program
Phase Clinical Study Plans Request Special Protocol Assessment Phase Trial
Policy Timing Equity Grants Pre-bla Meeting
Pre-existing Obligations Preclinical Clinical Developmental Sciences Development
Preparation Filing Tax Returns Payment Pricing
Primary Endpoint Reduction Annualized Relapse Rate Secondary Endpoints Product Operations Quality
Product Profit Products
Products Development Promotion
Property Rights Protect Patent Other Intellectual Property Rights Succeed
Provided Provisions Certificate Incorporation Bylaws Delaware Law Prevent Delay
Public Announcements Purchase Price Shall Meaning Set Forth Hereof
Purpose Formation Quality Agreement
Re-engagement Awards Recent Developments
Recitals Record Keeping
Records Reduced Royalty Rate
Reduces Full 2009 Cash Utilization Guidance Approximately Redwood City Calif Seattle Wash Aug 2009
Redwood City California 94063 Referral Executive Officers
Refunds Tax Sharing Agreements Regulation Disclosure
Regulatory Filings Regulatory Materials
Release Escrow Funds Rely Sole Source Parties Manufacture Products
Remaining Inventories Report Audit Committee
Reporting Reports
Representation Legal Counsel Representations Facet
Representations Trubion Representatives
Required Satisfy Certain Indemnification Obligations Pdl Not Able Research
Research Development Research Development Capabilities
Research Development Efforts Not Successful Able Effectively Develop Research Development Expenses
Research Development Programs Response Biogen Idecs Offer
Restricted Cash Restructuring Activities
Restructuring Charges Restructuring Plan
Results Operations Financial Condition Results Support Initiation Global Phase Study
Retention Bonuses Retention Bonuses Severance Benefits
Return Leased Property Licensed Software Revenue Recognition
Revenue Recognition Collaborative Arrangements Revenues
Revenues Geographic Area Significant Customers Review Approval Transactions Related Persons
Revised 2009 Guidance Richard Murawczyk
Rights Bankruptcy Rights Otherwise Prevent Production Disclosure Such Privileged Information
Risk Factors Robert Chapman
Roderick Wong Withdraws Director Nominations Role Committees
Rolfe Rolfe Joining Facet 20th New Senior Vice President
Royalties After Opt-out Due Competing Program Royalties After Opt-out Following Change Control
Royalty Product Reports Payments Royalty Products
Sale Manufacturing Assets Sale Manufacturing Assets Clinical Supply Agreement
Schedule 1132 Trubion Core Patent Rights Schedule 1134 Trubion Product Patent Rights
Schedule 14a Scientific Information
Scope Seaport Boulevard Redwood City 94063 Address Principal Executive
Seaport Boulevard Redwood City California 94063 Seaport Boulevard Redwood City California 94063 650 454-1000
Seaport Boulevard Redwood City California 94063 Address Principal Seattle Wash Redwood City Calif Dec 2009
Sec Filings Security Holders
Seen Announcement Yesterday Moving Forward Program Plan Request Segment Disclosures
Separation Separation Distribution Agreement
Services Services Term Termination
Severability Shall Meaning Set Forth Preamble Hereto
Shall Not Consummate Such Consolidation Merger Sale Unless Signature
Signatures Specific Responsibilities
Specific Responsibilities Jpc Specific Responsibility Jfc
Spread Shall Meaning Set Forth Hereof Standards Conduct
Standards Conduct Diligence Stock Shall Vote Together Class Matters Submitted Stockholders
Stock-based Compensation Stockholder Rights Plan Provisions Certificate Incorporation Bylaws Delaware
Stockholders Agreement Strategic Collaborations Licensing Agreements
Strategic Development Collaborations Subject Product Liability Claims Insurance Coverage Not Adequate
Subject Takeover Bid Disruptive Business Distract Management Employees Sublicensing
Submission Matters Vote Security Holders Subsequent Event-2009 Restructuring Activities
Subsequent Events Summary Financial Results
Summary Financial Results 2009 Summary Financial Results 2009 Outlook
Summary Financial Results Outlook Sure
Tax Contests Tax Sharing Indemnification Agreement
Taxes Withholding Ted Llana
Term Termination
Termination Facet Thereof Duly Validly Authorized Issued Fully Paid Nonassessable
Theres Still Lot Learned Elotuzumab Confident Team Place Total Cost Expenses 2009 Increased 529 512 Prior-year
Trademarks Transfer Facet Assets Assumption Liabilities Subject Sections
Transferred Asset Liability Shall Deemed Facet Respectively Subject Transition Assistance
Transition Services Agreement Tru-016
Tru-016 Description Trubion
Trubion Core Patent Rights Trubion Forward-looking Statements
Trubion Product Patent Rights Trubion Product Patent Rights Facet Joint
Trubion Royalties Trust Agreement Shall Meaning Set Forth Hereof
Unable Enroll Sufficient Number Patients Timely Manner Order Unable Obtain Maintain Regulatory Approval Products
Underpayments Overpayments Unless Clinical Studies Demonstrate Safety Efficacy Product Candidates
Updates Development Plan Upfront Payment
Valuation Assumptions Value Transfer Restricted Stock Awards
Value Transfer Stock Option Awards Vote Person
Vote Proxy Vote Shares Held Broker
Votes Required Approval Each Voting
Waiver Webcast Morgan Healthcare Conference Presentation
Weve Also Been Working Closely Number Leading Oncologists What Broker Non-votes
What Constitutes Quorum Annual Meeting What Householding
What Mean Receive Proxy Card What Receive Proxy Card Wong Entities
What Receive Separate Copy Annual Report Proxy Statement What Stockholders Vote Annual Meeting
Whereas Winds Down Activities Pdl Biopharma France Sas Such
Within Jsc Within Subcommittees
Witness Whereof 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki